FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington.	D.C.	20549

	3 ,		
STATEMENT (OF CHANGES IN	I BENEFICIAL	OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	urden								
hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Quan Venture Fund II, L.P.					2. Issuer Name and Ticker or Trading Symbol Design Therapeutics, Inc. [DSGN]							(5. Rela (Check	ationship of all applical Director	ble)	Perso	n(s) to Issue 10% Ow Other (s	ner	
(Last)	(F	First)	(Middle)		3. Date	of E	arliest Trans	action	n (Month	n/Day/	/Year)				below)	give title		below)	pecity
C/O MAPLES CORPORATE SERVICES LTD.,				03/30/2021															
P.O. BO	X 309, UGL	AND HOUSE																	
(Street) GRAND CAYMA	F	9	KY1-1104		4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Indiv Line) X	I							
(City)	(5	State)	(Zip)																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)		Date	Transaction ate donth/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Code (Instr.		ties Acquir I Of (D) (Ins				Form ly (D) or		Direct Indirect Istr. 4)	7. Nature of ndirect Beneficial Ownership			
								ode V	А	Mount	(A) (D)	or Pric	ce	Transactio (Instr. 3 an	on(s) id 4)			(Instr. 4)	
Common	non Stock 03/30/			2021			С		4,439,839		A	(1) 4,439		,839		D			
Common	Common Stock 03/30)/2021			С		280,991 A		A	(1)	4,720,830		330 D				
			Table II - I				ities Acq warrants								vned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Ye		3A. Deemed Execution Date if any (Month/Day/Ye	Cod	Transaction Code (Instr.		Derivative E		6. Date Exercisable and Expiration Date (Month/Day/Year)		e and	7. Title and Amou Securities Underl Derivative Securit (Instr. 3 and 4)		lying Derivative		9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Cod	e V	(A)	(D)	Date Exerc	cisable	Expi Date	iration e	Title	Amount Number Shares	rof		Transact (Instr. 4)			
Series A Preferred Stock	(1)	03/30/2021		С			7,236,938		(1)		(1)	Common Stock	4,439,	,839	(1)	0		D	
Series B Preferred Stock	(1)	03/30/2021		С			458,016		(1)		(1)	Common Stock	280,9	991	(1)	0		D	

Explanation of Responses:

1. All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

Remarks:

QUAN VENTURE FUND II, L.P., By: QUAN VENTURE PARTNERS II, L.L.C., its general partner, By: /s/ Stella

03/31/2021

Xu, Managing Director

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.